Y-90-Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients

Anton Hagenbeek, John Radford, Achiel Van Hoof, Umberto Vitolo, Ama Z. S. Rohatiner, Gilles Salles, Pierre Soubeyran, Herve Tilly, Angelika Bischof Delaloye, Wim L. J. van Putten, Franck Morschhauser

    Research output: Contribution to journalArticlepeer-review

    Cite this